rpa102
Vaccineexperimental
Clinical trial activity
5 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00103467)
Timeline
Indications
Studied for
Mechanism of action
- Bacillus anthracisImmunity, active
Bacillus anthracis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rpa102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01624532 | Phase 2 | Nov 1, 2011 | Government of Korea, Green Cross Corporation, Seoul National University |
| NCT00170456 | Phase 2 | Mar 1, 2005 | National Institute of Allergy and Infectious Diseases (NIAID), PharmAthene |
| NCT00170469 | Phase 2 | Mar 1, 2005 | Accelovance, National Institute of Allergy and Infectious Diseases (NIAID), PharmAthene |
| NCT00100724 | Phase 2 | Apr 1, 2004 | Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), VaxGen |
| NCT00103467 | Phase 1 | Jun 1, 2003 | VaxGen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 1 | 2004 |
| PharmAthene | For profit | 2 | 2 | 1 | 2005 |
| VaxGen | For profit | 2 | 2 | 2 | 2003 |
| Accelovance | For profit | 1 | 0 | 1 | 2005 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 0 | 1 | 2004 |
| Government of Korea | Government | 1 | 0 | 1 | 2011 |
| Green Cross Corporation | For profit | 1 | 1 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2004 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2011 |
9 organizations
Page 1 / 1